Skip to content
The Policy VaultThe Policy Vault

Mavenclad (cladribine) — Blue Cross Blue Shield of Illinois

Off-label use for patients under age 18 years (BCBS MT Fully Insured or MT HIM)

Initial criteria

  • The patient is under the age of 18 years
  • The patient does NOT have any FDA labeled contraindications
  • The patient has an indication supported in TWO articles from major peer-reviewed professional medical journals (JAMA, NEJM, Lancet) showing general safety and efficacy with acceptable study designs (randomized, double blind, placebo controlled clinical trials)
  • There is support for an age in the patient’s given age bracket (infancy 0-<2 years, childhood 2-11 years, adolescence 12-17 years) in TWO such peer-reviewed articles as generally safe and effective